2020 Q1 Form 10-Q Financial Statement
#000156459020023640 Filed on May 08, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $7.490M | $2.012M |
| YoY Change | 272.27% | 116.81% |
| Cost Of Revenue | $980.0K | $330.0K |
| YoY Change | 196.97% | |
| Gross Profit | $6.510M | $1.682M |
| YoY Change | 287.04% | |
| Gross Profit Margin | 86.92% | 83.6% |
| Selling, General & Admin | $12.49M | $11.92M |
| YoY Change | 4.73% | 422.85% |
| % of Gross Profit | 191.78% | 708.74% |
| Research & Development | $4.853M | $3.797M |
| YoY Change | 27.81% | 14.2% |
| % of Gross Profit | 74.55% | 225.74% |
| Depreciation & Amortization | $33.00K | $44.00K |
| YoY Change | -25.0% | 2.33% |
| % of Gross Profit | 0.51% | 2.62% |
| Operating Expenses | $18.93M | $16.66M |
| YoY Change | 13.62% | 197.24% |
| Operating Profit | -$11.44M | -$14.65M |
| YoY Change | -21.89% | 213.19% |
| Interest Expense | $1.784M | $1.020M |
| YoY Change | 74.9% | -144.35% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$1.730M | -$4.587M |
| YoY Change | -62.28% | 99.43% |
| Pretax Income | -$13.17M | -$19.24M |
| YoY Change | -31.55% | 175.64% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$13.17M | -$19.24M |
| YoY Change | -31.52% | 175.7% |
| Net Earnings / Revenue | -175.89% | -956.16% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.140M | -$2.015M |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $26.30M | $43.40M |
| YoY Change | -39.4% | 166.26% |
| Cash & Equivalents | $26.45M | $43.38M |
| Short-Term Investments | ||
| Other Short-Term Assets | $5.600M | $1.800M |
| YoY Change | 211.11% | 100.0% |
| Inventory | $3.400M | $886.0K |
| Prepaid Expenses | ||
| Receivables | $14.40M | $2.300M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $49.70M | $48.37M |
| YoY Change | 2.75% | 173.67% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.400M | $425.0K |
| YoY Change | 700.0% | 70.0% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $200.0K | $200.0K |
| YoY Change | 0.0% | -33.33% |
| Total Long-Term Assets | $30.60M | $33.48M |
| YoY Change | -8.61% | 3.08% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $49.70M | $48.37M |
| Total Long-Term Assets | $30.60M | $33.48M |
| Total Assets | $80.30M | $81.85M |
| YoY Change | -1.9% | 63.19% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.200M | $6.318M |
| YoY Change | -17.7% | 128.91% |
| Accrued Expenses | $5.100M | $2.924M |
| YoY Change | 74.42% | -9.05% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $10.30M | $24.66M |
| YoY Change | -58.23% | 16.23% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $47.80M | $31.95M |
| YoY Change | 49.6% | 148.65% |
| Other Long-Term Liabilities | $5.800M | $2.100M |
| YoY Change | 176.19% | 123.88% |
| Total Long-Term Liabilities | $53.60M | $34.05M |
| YoY Change | 57.41% | 146.97% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $10.30M | $24.66M |
| Total Long-Term Liabilities | $53.60M | $34.05M |
| Total Liabilities | $63.80M | $61.98M |
| YoY Change | 2.94% | 47.7% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$427.7M | |
| YoY Change | 29.79% | |
| Common Stock | $446.8M | |
| YoY Change | 32.6% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $16.47M | $19.88M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $80.30M | $81.85M |
| YoY Change | -1.9% | 63.19% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$13.17M | -$19.24M |
| YoY Change | -31.52% | 175.7% |
| Depreciation, Depletion And Amortization | $33.00K | $44.00K |
| YoY Change | -25.0% | 2.33% |
| Cash From Operating Activities | -$16.35M | -$13.33M |
| YoY Change | 22.58% | 176.7% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $16.00K | $182.0K |
| YoY Change | -91.21% | |
| Acquisitions | $0.00 | |
| YoY Change | -100.0% | |
| Other Investing Activities | $0.00 | |
| YoY Change | -100.0% | |
| Cash From Investing Activities | -$16.00K | -$182.0K |
| YoY Change | -91.21% | -98.79% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $20.29M | $0.00 |
| YoY Change | -100.0% | |
| Debt Paid & Issued, Net | $20.00M | |
| YoY Change | ||
| Cash From Financing Activities | 20.45M | 11.63M |
| YoY Change | 75.74% | -50.2% |
| NET CHANGE | ||
| Cash From Operating Activities | -16.35M | -13.33M |
| Cash From Investing Activities | -16.00K | -182.0K |
| Cash From Financing Activities | 20.45M | 11.63M |
| Net Change In Cash | 4.085M | -1.882M |
| YoY Change | -317.06% | -154.24% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$16.35M | -$13.33M |
| Capital Expenditures | $16.00K | $182.0K |
| Free Cash Flow | -$16.36M | -$13.52M |
| YoY Change | 21.05% | 180.47% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
481000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
19877000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4587000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13174000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19238000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.11 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.20 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
95452000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13174000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-19238000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37633000 | |
| CY2020Q1 | eypt |
Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
|
980000 | |
| CY2019Q1 | eypt |
Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
|
330000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4853000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3797000 | |
| CY2020Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
8125000 | |
| CY2019Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
7311000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4360000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4610000 | |
| CY2020Q1 | eypt |
Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
|
615000 | |
| CY2019Q1 | eypt |
Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
|
615000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
18933000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
16663000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11444000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14651000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
54000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
243000 | |
| CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
1784000 | |
| CY2019Q1 | us-gaap |
Interest Expense
InterestExpense
|
1020000 | |
| CY2020Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
| CY2019Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-3810000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1730000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
115530000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
0 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
264000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1160000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-13174000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19238000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
-20000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1238000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
19990000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
187000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
-19000 | |
| CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
615000 | |
| CY2019Q1 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
2716000 | |
| CY2020Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
19000 | |
| CY2019Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
615000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
33000 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
44000 | |
| CY2020Q1 | eypt |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
171000 | |
| CY2019Q1 | eypt |
Amortization Of Debt Discount
AmortizationOfDebtDiscount
|
140000 | |
| CY2020Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
323000 | |
| CY2019Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
112000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1160000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1238000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
|
2320000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
|
2046000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1221000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
607000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-1944000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2593000 | |
| CY2020Q1 | eypt |
Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
|
-3000 | |
| CY2019Q1 | eypt |
Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
|
35000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
15000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-30000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16345000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13334000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
16000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
182000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-16000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-182000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
20285000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
35000000 | |
| CY2019Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
894000 | |
| CY2019Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
20000000 | |
| CY2019Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
20000 | |
| CY2020Q1 | eypt |
Proceeds From Stock Options Exercised And Employee Stock Purchase Plan
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlan
|
187000 | |
| CY2019Q1 | eypt |
Proceeds From Stock Options Exercised And Employee Stock Purchase Plan
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlan
|
264000 | |
| CY2020Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
7000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
20446000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11634000 | |
| CY2020Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | |
| CY2019Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
4085000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1882000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
22364000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
45411000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26449000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43529000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1290000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1111000 | |
| CY2020Q1 | eypt |
Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
|
295000 | |
| CY2019Q1 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
222000 | |
| CY2019Q1 | eypt |
Debt Instrument Exit Fee
DebtInstrumentExitFee
|
2100000 | |
| CY2020Q1 | eypt |
Principal Portion Of Finance Lease Liabilities
PrincipalPortionOfFinanceLeaseLiabilities
|
7000 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-top:10pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:10pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Operations and Basis of Presentation  </p></td></tr></table></div> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the “Company”) as of March 31, 2020 and for the three months ended March 31, 2020 and 2019 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2019, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period. </p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of serious eye disorders. <font style="Background-color:#FFFFFF;color:#000000;">The Company has two products, YUTIQ</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup></font><font style="Background-color:#FFFFFF;color:#000000;"> and DEXYCU</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup></font><font style="Background-color:#FFFFFF;color:#000000;">, which were approved by the U.S. Food and Drug Administration (“FDA”) in 2018.</font></p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, was launched directly in the U.S. in February 2019. YUTIQ is indicated for the treatment of chronic </font>non-infectious<font style="Background-color:#FFFFFF;"> uveitis affecting the posterior segment of the eye, which affects between 60,000 to 100,000 people in the U.S. each year and causes approximately 30,000 new cases of blindness every year, making it the third leading cause of blindness. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained constant (zero order release) basis for up to 36 months. YUTIQ is based on the Company’s proprietary Durasert</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup></font><font style="Background-color:#FFFFFF;"> sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years.</font></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">DEXYCU (dexamethasone intraocular suspension) 9%, </font>for intraocular administration, was launched directly in the U.S. in March 2019. Indicated for the treatment of post-operative ocular inflammation, DEXYCU <font style="Background-color:#FFFFFF;">is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for this indication. DEXYCU utilizes the Company’s proprietary Verisome</font><sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup><font style="Background-color:#FFFFFF;"> drug-delivery platform, which allows for a single intraocular injection that releases dexamethasone, a corticosteroid, over time. There were approximately 3.8 million cataract surgeries performed during 2018 in the U.S.</font><font style="font-size:12pt;color:#000000;"> </font><font style="Background-color:#FFFFFF;">and the Company launched DEXYCU with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (“Icon”) in March 2018 (the Icon Acquisition”). </font></p> <p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ILUVIEN<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> for diabetic macular edema (“DME”), the Company’s licensed product, is sold directly in the U.S. and several European Union (“EU”) countries by Alimera Sciences, Inc. (“Alimera”). In July 2017, the Company expanded its license agreement with Alimera to include the uveitis indication utilizing the Durasert technology in Europe, the Middle East and Africa (“EMEA”), which received European regulatory approval in March 2019 and, subject to obtaining pricing and reimbursement in each applicable country, will be marketed as ILUVIEN. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EYP-1901, 6-Month bioerodible Durasert Vorolanib – Tyrosine Kinase Inhibitor (“TKI”) is being advanced as a potential treatment for wet age-related macular degeneration (“wAMD”) with potential in diabetic retinopathy (“DR”) and retinal vein occlusion (“RVO”). The Company has completed initial animal pharmacokinetic and toxicology studies before 2020 and initiated GLP toxicology studies in March 2020 to support the anticipated filing of an Investigational New Drug application with the FDA later this year, </font>with a Phase 1 clinical trial scheduled to follow shortly afterwards<font style="Background-color:#FFFFFF;">.</font>  <font style="Background-color:#FFFFFF;color:#000000;"> </font> <font style="Background-color:#FFFFFF;color:#000000;"> </font></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.</font><font style="color:#000000;"> The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners</font><font style="Background-color:#FFFFFF;">.</font><font style="color:#000000;"> In the first quarter of 2019, the Company commenced the U.S. launch of its first two commercial products, YUTIQ and DEXYCU. However, management does not yet have sufficient historical evidence to assert that it is probable that the Company will receive sufficient revenues from its product sales to fund operations. As of March 31, 2020, the Company has had recurring operating losses since its inception and has an accumulated deficit of approximately $478.5 million and working capital of $39.4 million. The Company had cash and cash equivalents of $26.3 million at March 31, 2020. </font></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, the foregoing conditions, taken together, continue to raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s plans that are intended to mitigate those conditions include continuing to fulfill its funding needs through cash inflows from revenue of YUTIQ and DEXYCU product sales, licensing arrangements, additional capital raises or other arrangements. <font style="Background-color:#FFFFFF;color:#000000;">The Company’s plans also include a restructuring plan and curtailing expenses to conserve cash in response to a significant decline in product demand associated with shut-downs of customer facilities and postponements of elective surgical procedures and physician office visits in response to the COVID-19 coronavirus pandemic (the “Pandemic”). </font> On April 8, 2020, the Company submitted an application through Silicon Valley Bank for the Paycheck Protection Program Loan (the “PPP Loan”) <font style="Background-color:#FFFFFF;color:#000000;">that is administered by the U.S. Small Business Administration (the “SBA”),</font><font style="Background-color:#FFFFFF;color:#212529;"> under </font>the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”)<font style="Background-color:#FFFFFF;color:#000000;">. </font>On April 22, 2020, the Company received the PPP Loan proceeds of $2.0 million. The Company believes that its cash and cash equivalents of $26.3 million at March 31, 2020, the PPP Loan proceeds of $2.0 million received on April 22, 2020, and expected cash inflows under its product sales and royalty agreements coupled with cash conservation activities will enable the Company to fund its current and planned operations into 2021 under current assumptions for the duration of the COVID-19-related closures across the U.S. Although the Company believes such plans, if executed, should provide the Company sufficient financing to meet its needs, there is no assurance that additional funding will be achieved and that the Company will succeed in its future operations. Actual cash requirements could differ from management’s projections due to many factors, including the success of commercialization for YUTIQ and DEXYCU, the actual costs of these commercialization efforts, additional investments in research and development programs, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</font><font style="color:#000000;"> (“ASU 2016-13”)</font><font style="font-style:italic;">: Measurement of Credit Losses on Financial Instruments,</font> to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of this standard did not have<font style="color:#000000;"> a material impact on its consolidated financial statements. </font></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740)</font><font style="color:#000000;"> (“ASU 2019-12”)</font><font style="font-style:italic;">: Simplifying the Accounting for Income Taxes.</font> The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. This standard will be effective for the Company in the first quarter of its fiscal year ending December 31, 2021. The Company is<font style="color:#000000;"> currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</font></p> | |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
38193000 | |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
213000 | |
| CY2020Q1 | us-gaap |
Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
|
1976000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
|
0 | |
| CY2019Q1 | eypt |
Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
|
265000 | |
| CY2019Q1 | eypt |
Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
|
-8000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
|
257000 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
68322000 | |
| CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
68322000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
68322000 | |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
68322000 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
40653000 | |
| CY2020Q1 | eypt |
Number Of Products Approved
NumberOfProductsApproved
|
2 | |
| CY2020Q1 | eypt |
Working Capital
WorkingCapital
|
39400000 | |
| CY2020Q1 | eypt |
Accrued Sales Based Royalty Expense
AccruedSalesBasedRoyaltyExpense
|
517000000 | |
| CY2019Q1 | eypt |
Accrued Sales Based Royalty Expense
AccruedSalesBasedRoyaltyExpense
|
99000000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
|
2241000 | |
| CY2020Q1 | eypt |
Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
|
1048000 | |
| CY2020Q1 | eypt |
Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
|
-217000 | |
| CY2020Q1 | eypt |
Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
|
-1096000 | |
| CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
41268000 | |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
38808000 | |
| CY2019Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
29514000 | |
| CY2020Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1715000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3263000 | |
| CY2020Q1 | eypt |
Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
|
56000 | |
| CY2019Q4 | eypt |
Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
|
345000 | |
| CY2020Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
429000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
700000 | |
| CY2020Q1 | eypt |
Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
|
1508000 | |
| CY2019Q4 | eypt |
Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
|
1889000 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
851000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
635000 | |
| CY2020Q1 | us-gaap |
Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
|
P5Y | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.125 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
502000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
481000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3266000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3379000 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
213000 | |
| CY2020Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
486812 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
9000 | |
| CY2019Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
9000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
215000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
178000 | |
| CY2020Q1 | eypt |
Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
|
100000 | |
| CY2020Q1 | eypt |
Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
|
14000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
86000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
49000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
38000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
| CY2020Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
87000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
14000 | |
| CY2020Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
3000 | |
| CY2020Q1 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
2000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y8M12D | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.125 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
652000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
889000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
849000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
815000 | |
| CY2020Q1 | eypt |
Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
|
1176000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
4381000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1115000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
42000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
55000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
97000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
10000 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
486812 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
486812 | |
| CY2020Q1 | eypt |
Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
|
0 | |
| CY2019Q1 | eypt |
Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
|
0 | |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
486812 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.23 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.23 | |
| CY2020Q1 | eypt |
Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
|
0 | |
| CY2019Q1 | eypt |
Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
|
0 | |
| CY2020Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.23 | |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.23 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1160000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1238000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
5700000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y7M2D | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16777801 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11066008 |
